Skip to main content
OpenTrials
Completed

NCT Number: NCT04059952

Mechanism of Action of Electroconvulsive Therapy

This is an observational neuroimaging study assessing the effects of ECT on the brains of patients with unipolar and bipolar depression.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02129, United States

About this study

This project aims to use functional connectivity magnetic resonance imaging (fcMRI) to study patients with unipolar and bipolar depression receiving ECT. Patients will be scanned before and after a full course of ECT and clinical measures for depression severity and memory will be obtained at the same times.The project has the following aims and hypothesis: (1) to determine the therapeutic antidepressant mechanism of action of ECT at the circuit level (2) to determine the mechanism of action of iatrogenic amnesia caused by ECT at the circuit level (3) to study the use of fcMRI as a state biomarker for depression (4) to study the use of fcMRI as a predictor of response for depression.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and Females Between Ages of 18 and 65
  • Diagnosis of Major Depressive Disorder without Psychotic Features or Bipolar I/II
  • Requiring ECT Treatment as Part of Psychiatric Care

Exclusion criteria

  • Comorbid diagnoses of Major Depressive Disorder with Psychotic Features, Schizoaffective Disorder, Schizophrenia or Dementia
  • History of Psychosis
  • Substance Use Disorder (Abuse or Dependence) with Active Use Within Last 6 Months
  • Severe or Unstable Medical Illness
  • Medical Contraindication to Anesthesia or ECT (e.g., Recent Myocardial Infarction)

Treatment and study plan

Electroconvulsive therapy

Device

Electrical currents are passed through the brain to intentionally trigger a controlled seizure in order to produce a therapeutic change in neuro-chemistry and circuitry.

Primary outcomes

  1. Changes in Functional Connectivity of Key Nodes

    Time frame: Through Treatment Completion, Average of 2 Months

    Measured by Magnetic Resonance Imaging, Key Nodes include Subgenual Cingulate, Dorsal Anterior Cingulate, Nucleus Accumbens, Hippocampus, Amygdala and Dorsolateral Prefrontal Cortex

Secondary outcomes

  1. Changes in Functional Connectivity of Memory Circuits

    Time frame: Through Treatment Completion, Average of 2 Months

    Measured by Magnetic Resonance Imaging, Memory Circuits Include Hippocampus and Dorsolateral Prefrontal Memory Hubs

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Registry information

Acronym: MoA-ECT

Important dates

Study start
2019
Primary completion
2024
Study completion
2024
First posted
Aug 16, 2019
Registry last updated
Jun 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.